http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2705797-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2014-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0fa8300b89e7b81a0c4d9d285bf0e18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16d599438e9e9960cb75b4d3325f5753 |
| publicationDate | 2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2705797-C2 |
| titleOfInvention | Treating diabetes mellitus with long-acting insulin formulations |
| abstract | FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention refers to pharmaceutical industry, namely to a method for treating type I or type II diabetes mellitus. Method of treating type I or type II diabetes mellitus, comprising administering the aqueous pharmaceutical formulation once a day, where the time interval after the previous administration is in range of 24.5 h to 28 h or in range of 20 h to 23.5 h for at least two days a week, and where the average time interval after the previous administration is approximately 24 hours, where composition contains 300 IU/ml of glargine insulin [equimolarly 300 IU of human insulin].EFFECT: presented method of treating type I or type II diabetes mellitus is effective, safe and reduces a risk of developing nocturnal hypoglycaemia.12 cl, 15 dwg, 76 tbl, 6 ex |
| priorityDate | 2013-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 217.